Serial growth of human malignant fibrous histiocytoma xenografts in immunodeficient mice.

Abstract

Malignant fibrous histiocytoma (MFH) is on of the most common soft tissue sarcomas of adulthood, the only treatment for which involves surgical resection of the extremities and retroperitoneum, while no standard postoperative adjuvant chemotherapy has been established. We report herein on the establishment of a serially transplantable MFH strain in immunodeficient mice. An intraperitoneal tumor was resected from a patient with multiple recurrent MFH, inoculated into the subcutaneous tissue of mice with severe combined immunodeficiency (SCID), and established as a serially transplantable MFH strain, MH-1. The chemosensitivity of MH-1 was similar to that of the original fresh surgical specimen, as confirmed by the 3-(4,5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H tetrazolium bromide (MTT) test. We believe that this serially transplantable strain will be useful for further studies on chemotherapy effective against MFH.

• Authors: N Kurihara, T Kubota, Y Otani, M Watanabe, K Kumai, M Kitajima
• Journal: Surgery today (Surg Today) Vol. 26 Issue 4 Pg. 267-70 ( 1996) ISSN: 0941-1291 [Print] Japan
• PMID: 8727948 (Publication Type: Case Reports, Journal Article)

Topics

• Abdominal Neoplasms (pathology, surgery)
• Animals
• Cell Division (physiology)
• Histiocytoma, Benign Fibrous (pathology, surgery)
• Humans
• Ileal Neoplasms (pathology, surgery)
• Mice
• Mice, SCID
• Middle Aged
• Neoplasm Recurrence, Local (pathology, surgery)
• Neoplasm Transplantation
• Reoperation
• Soft Tissue Neoplasms (pathology, surgery)
• Tumor Cells, Cultured
• Tumor Stem Cell Assay